Erythromycin pharma grade API, designated CAS 114-07-8, is a fermentation-derived 14-membered macrolide obtained from Saccharopolyspora erythraea. The free base is supplied as a crystalline dihydrate for oral solid-dosage processing; the unmodified free base is not appropriate for sterile injection because of low aqueous solubility and acid lability. Supplier-specific product codes distinguish the micronized oral direct-compression grade, the coarser oral granulation grade, and the water-soluble lactobionate salt for parenteral use. The oral-grade dihydrate is a white to off-white crystalline powder with pH-dependent low water solubility and a bitter taste. Pharmacopoeial compliance is assessed against the current USP Erythromycin monograph and the Ph.Eur. Erythromycin monograph; residual solvent testing follows ICH Q3C and USP <467>, elemental impurities follow ICH Q3D and USP <232>, and non-sterile microbiological quality is controlled by USP <61> and USP <62>.

Typical release controls for the oral-grade dihydrate include appearance, identification by infrared spectrophotometry and HPLC retention time, water content by Karl Fischer titration, residue on ignition, specific optical rotation, and assay/potency by HPLC or microbiological method. The assay is expressed as erythromycin A activity on an anhydrous basis; current pharmacopoeial monographs set the acceptance range near 920–1000 μg/mg for the free base. Chromatographic purity is assessed with a buffered mobile phase at pH 8.0; the method must resolve erythromycin A from erythromycin B, erythromycin C, and related degradation products. The free base is a non-sterile material; therefore, it is not supplied with a sterility claim unless a specific contract manufacturing arrangement is used.

Why Is Particle Size Distribution Controlled Differently for Direct Compression Than for Wet Granulation?

Particle size is not a single specification for erythromycin base; it is matched to the intended granulation route, compression equipment, and filling method. A micronized grade with D50 20–40 μm and D90 below 80 μm is used for direct compression and low-fill-weight capsule blends, while a sieved grade with D50 80–120 μm and D90 below 200 μm is selected for high-shear wet granulation because the subsequent densification step reduces segregation risk. Particle size is measured by laser diffraction per ISO 13320-1:2020 after dispersion in a saturated non-solvent; dry dispersion may cause particle attrition and should be validated against wet dispersion. Flow behaviour is characterised by ASTM D6393-21; direct-compression blends with Carr index above 30 frequently show insufficient die fill on high-speed rotary tablet presses. Batch-to-batch variation in the micronized grade has been observed on production-scale presses as punch filming when the blend moisture content exceeds 4.0% w/w and when magnesium stearate is mixed for more than 5 min in a bin blender. The processing boundary is controlled by drying granulation at product temperature below 50 °C, adding lubricant in the final 2–3 min, and maintaining press tooling at a surface temperature below 40 °C.

For tablet and capsule dosage forms, the free base is acid-labile; unprotected oral administration would degrade in gastric acid. Tablet cores are therefore enteric-coated, or the formulation uses an acid-resistant erythromycin salt such as stearate. The free base is blended with microcrystalline cellulose, croscarmellose sodium, and a binder such as povidone; aqueous wet granulation is run with water adjusted to pH 6.5–8.0 to suppress acid-catalysed ring-opening and N-demethylation. Granule drying in a fluid-bed dryer is maintained with an inlet air temperature that keeps product temperature below 50 °C; published degradation rate data vary with water activity and granule porosity, but thermal exposure above this threshold accelerates loss of erythromycin A. The dried granulate is compressed to a core hardness verified by tablet breaking force per USP <1217> and friability per USP <1216>.USP <711> dissolution testing for enteric-coated tablets uses 0.1 N HCl acid stage for 2 h followed by a pH 6.8 phosphate buffer stage; the acid-stage release must remain below the monograph limit to confirm coating integrity. Capsule filling is performed on automatic capsule machines; content uniformity is verified per USP <905>, and segregation during hopper discharge is minimised by keeping the API and excipient blend bulk densities within 0.05 g/mL of each other.

For granule dosage forms, wet granulation is used to improve flow and content uniformity rather than relying on a simple dry blend. High-shear granulators with impeller speed in the range of 300–500 rpm and chopper speed below 1200 rpm are used for densification; the wet mass is passed through a 1.2–1.8 mm sieve and dried in a fluid-bed dryer. A top-spray fluid-bed granulator can be used for granulation and drying in a single vessel; inlet air temperature is maintained at 45–55 °C, and product temperature is kept below 50 °C. Over-granulation produces hard granules with poor compressibility and retarded dissolution; under-granulation produces fine particles that segregate in the hopper. Dissolution testing per USP <711> is used to confirm that the granule releases in the specified buffer stage after enteric coating.

If Sterile Injectable Administration Is Required, the Free Base Dihydrate Must Be Replaced by a Water-Soluble Macrolide Salt

Erythromycin base dihydrate has low aqueous solubility below 2 mg/mL at neutral pH and therefore cannot be dissolved to the concentrations required for parenteral dosing. Erythromycin lactobionate is the salt used for sterile injection; it is supplied as a sterile lyophilized powder or concentrated solution with water solubility above 100 mg/mL at 25 °C. The injectable grade is manufactured using aseptic processing after filtration, or by terminal sterilization where compatible; release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, and USP <790> visible particulates. Reconstitution uses water for injection; the final infusion concentration and duration are determined by venous tolerance, but the product is not administered as a rapid bolus because of pH and vein irritation. The injectable salt is not interchangeable with the oral free base in wet granulation or direct compression; it is water-soluble and can be hygroscopic, which creates different handling and packaging requirements.

Impurity control for the pharma grade free base is conducted under ICH Q3A and ICH Q3B. Erythromycin-related substances including erythromycin B, erythromycin C, N-demethylerythromycin A, anhydroerythromycin A, and erythromycin A enol ether are resolved by HPLC using a buffered mobile phase at pH 8.0; current pharmacopoeial monographs impose specified limits for total impurities and individual impurities. Residual solvents are controlled by USP <467> and Ph.Eur. 5.4. Crystallization and washing often use acetone and ethyl acetate; process-specific limits for each class 3 solvent are typically set below 0.5% w/w. Elemental impurity risk is evaluated under ICH Q3D; for fermentation-derived macrolides, the assessment includes chromium, nickel, and molybdenum because stainless steel crystallization and drying equipment may be used. Microbiological release for the oral-grade API is not a sterility claim but a bio-burden limit; total aerobic microbial count is generally controlled below 100 CFU/g and total combined yeasts/moulds below 20 CFU/g. The injectable lactobionate grade carries additional endotoxin and sterility controls because parenteral administration bypasses the gastrointestinal barrier.

Compared with azithromycin and clarithromycin, erythromycin has a shorter acid-stable half-life and a narrower range of acid-stable oral formulation options. Within the erythromycin product category, the pharma-grade base differs from feed-grade thiocyanate in that the pharma grade is manufactured under cGMP per 21 CFR Part 210 and 21 CFR Part 211, with batch review, documentation, and release not applied to feed-grade material. Erythromycin stearate and erythromycin ethylsuccinate are not interchangeable with the free base in direct compression without redeveloping the formulation because their particle size, bulk density, acid-lability profile, and dissolution behaviour differ.

Polymorph, Hydrate, and Physical Stability Controls for Fermentation-Derived Erythromycin Base

Erythromycin base is manufactured as the dihydrate; excessive drying at high temperature can generate anhydrous or monohydrate phases with altered compaction behaviour and reduced chemical stability. X-ray powder diffraction is performed per USP <941> to confirm the dihydrate pattern against a reference standard. Water content by Karl Fischer titration is controlled between 4.5% and 5.5% w/w for the oral dihydrate grade. The API is stored in tight, light-resistant containers at controlled room temperature 20–25 °C; relative humidity above 60% can increase surface moisture and promote crystal bridging in bulk storage, while prolonged very low-humidity storage can remove lattice water from the dihydrate. The free base is incompatible with strong acids, oxidizing agents, and prolonged contact with low-pH granulation fluids. It should not be co-milled with strongly acidic excipients because acid-catalysed degradation to anhydroerythromycin A can reduce assay. If warehouse humidity exceeds 65% RH, pre-drying at 40 °C in a vacuum dryer may be required before direct compression; the vacuum-drying step must be validated to avoid hydrate transition. The oral free base should not be held in open bins for extended periods in high-humidity rooms.